cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1618Research ArticleОБЗОР ЛИТЕРАТУРЫLITERATURE REVIEWМочевая кислота – ключевой компонент “кардиоренометаболического континуума”Uric acid – the key component of “cardio-reno-metabolic continuum”КобалаваЖ. Д.KobalavaZh. D.Kotovskaya@bk.ruКотовскаяЮ. В.KotovskayaYu. V.Kotovskaya@bk.ruТолкачеваВ. В.TolkachevaV. V.Kotovskaya@bk.ruМильтоА. С.MiltoA. S.Kotovskaya@bk.ruРоссийский университет дружбы народовRussian University of People’s FriendshipГородская клиническая больница № 64 г. МосквыMoscow City Clinical Hospital No. 64. Moscow2008200820087495100Copyright © Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Мильто А.С., 20082008Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Мильто А.С.Kobalava Z.D., Kotovskaya Y.V., Tolkacheva V.V., Milto A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1618мочевая кислотариск развития сердечно-сосудистых осложненийартериальная гипертонияметаболический синдромuric acidcardiovascular event riskarterial hypertensionmetabolic syndromeReferencesМоисеев B.C., Кобалава Ж.Д.. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин фармак тер 2002; 11(3): 16-8.Моисеев B.C., Кобалава Ж.Д.. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин фармак тер 2002; 11(3): 16-8.Мухин Н.А., Моисеев С.В., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер архив 2004; 6: 39-46.Мухин Н.А., Моисеев С.В., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер архив 2004; 6: 39-46.Тареев Е.М. Гипертоническая болезнь. Москва "Медицина" 1948.Тареев Е.М. Гипертоническая болезнь. Москва "Медицина" 1948.Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония: основные положения современных руководств. Москва 2005; 96 с.Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония: основные положения современных руководств. Москва 2005; 96 с.Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-53.Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-53.Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации, 2-й пересмотр, www.cardiosite.ruПрофилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации, 2-й пересмотр, www.cardiosite.ruMancia G., De Backer G., Dominiczak A., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.Mancia G., De Backer G., Dominiczak A., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.Johnson R.J., Kang D-H., Feig D., et al. Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease? Hypertension 2003; 41: 1183-90.Johnson R.J., Kang D-H., Feig D., et al. Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease? Hypertension 2003; 41: 1183-90.Johnson R.J., Feig D.I., Nakagawa T., et al. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 2008; 26: 381-91.Johnson R.J., Feig D.I., Nakagawa T., et al. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 2008; 26: 381-91.Бугаева Н.В., Балкаров И.М. Артериальная гипертония и нарушение пуринового обмена. Тер архив 1996; 68(1): 36-9.Бугаева Н.В., Балкаров И.М. Артериальная гипертония и нарушение пуринового обмена. Тер архив 1996; 68(1): 36-9.Мухин Н.А, Балкаров И.М., Моисев С.В. и др. Хронические прогрессирующие нефропатии и образ жизни современного человека. Тер архив 2004; 9: 5–10.Мухин Н.А, Балкаров И.М., Моисев С.В. и др. Хронические прогрессирующие нефропатии и образ жизни современного человека. Тер архив 2004; 9: 5–10.Johnson RJ, Kivlighn SD, Kim YG, et al. Reappraisal of the Pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kid Dis 1999; 33: 225–34.Johnson RJ, Kivlighn SD, Kim YG, et al. Reappraisal of the Pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kid Dis 1999; 33: 225–34.Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553–62.Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553–62.Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739–42.Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739–42.Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressureindependent mechanism. Am J Physiol Renal Physiol 2002; 282: F991–7.Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressureindependent mechanism. Am J Physiol Renal Physiol 2002; 282: F991–7.Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355–60.Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355–60.Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290: F625–31.Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290: F625–31.Johnson RJ, Titte S, Cade JR, et al. Uric acid, evolution and primitive cultures. Semin Nephrol 2005; 25: 3–8.Johnson RJ, Titte S, Cade JR, et al. Uric acid, evolution and primitive cultures. Semin Nephrol 2005; 25: 3–8.Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994; 8: 677–81.Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994; 8: 677–81.Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42: 474–80.Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42: 474–80.Sundstrom J, Sullivan L, D’Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28–33.Sundstrom J, Sullivan L, D’Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28–33.Feig DI, Nakagawa T, Karumanchi SA, et al. Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004; 66: 281–7.Feig DI, Nakagawa T, Karumanchi SA, et al. Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004; 66: 281–7.Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293: C584–96.Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293: C584–96.Puig GJ, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999; 17: 869–72.Puig GJ, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999; 17: 869–72.Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Караулова Ю.Л. Мочевая кислота-маркер и/или новый фактор рискаразвития сердечно-сосудистых осложнений? Клин фармак тер 2002; 11(3): 32–9.Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Караулова Ю.Л. Мочевая кислота-маркер и/или новый фактор рискаразвития сердечно-сосудистых осложнений? Клин фармак тер 2002; 11(3): 32–9.Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951; 34: 1421–31.Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951; 34: 1421–31.Fessel WJ. High uric acid as an indicator of cardiovascular disease. Independence from obesity. Am J Med 1980; 68: 401–4.Fessel WJ. High uric acid as an indicator of cardiovascular disease. Independence from obesity. Am J Med 1980; 68: 401–4.Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 1987; 82: 421–6.Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 1987; 82: 421–6.Alderman MH. Serum Uric Acid As a Cardiovascular Risk Factor for Heart Disease. Current Hypertens Reports 2001, 3: 184–9.Alderman MH. Serum Uric Acid As a Cardiovascular Risk Factor for Heart Disease. Current Hypertens Reports 2001, 3: 184–9.Fang J, Alderman MN. Serum uric acid and cardiovascular mortality – The NHANES 1 Epidemiologic Follow-up Study 1971–1992. JAMA 2000; 283: 2404–10.Fang J, Alderman MN. Serum uric acid and cardiovascular mortality – The NHANES 1 Epidemiologic Follow-up Study 1971–1992. JAMA 2000; 283: 2404–10.Levine W, Dyer AR, Shekelle RB, et al. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989; 42: 257–67.Levine W, Dyer AR, Shekelle RB, et al. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989; 42: 257–67.Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: atherosclerosis risk in communities (ARIC) Study. Ann Epidemiol 2000; 10: 136–43.Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: atherosclerosis risk in communities (ARIC) Study. Ann Epidemiol 2000; 10: 136–43.Verdecchia P, Schillaci G, Reboldi GP, et al. The relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072–8.Verdecchia P, Schillaci G, Reboldi GP, et al. The relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072–8.Langford HG, Blaufox MD, Borhani NO, et al. Is thiazideproduced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 1987; 147: 645–9.Langford HG, Blaufox MD, Borhani NO, et al. Is thiazideproduced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 1987; 147: 645–9.Alderman MH, Cohen H, Madhavean S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144–50.Alderman MH, Cohen H, Madhavean S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144–50.Franse LV, Pahor M, DiBari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149–54.Franse LV, Pahor M, DiBari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149–54.Chamorro A, Obach V, Cervera A, et al. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 2002; 33: 1048–52.Chamorro A, Obach V, Cervera A, et al. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 2002; 33: 1048–52.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.Ruilope LM, Kirwan B-A, de Brouwer S, et al. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. J Hypertensi 2007; 25: 1711–8.Ruilope LM, Kirwan B-A, de Brouwer S, et al. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. J Hypertensi 2007; 25: 1711–8.Reyes A J, Leary WP. The increase in serum uric acid induced by diuretics could be beneficial to cardiovascular prognosis in hypertension: a hypothesis. J Hypertens 2003; 21: 1775–7.Reyes A J, Leary WP. The increase in serum uric acid induced by diuretics could be beneficial to cardiovascular prognosis in hypertension: a hypothesis. J Hypertens 2003; 21: 1775–7.Кобалава Ж.Д. Клиническое и фармакодинамическое обоснование выбора антигипертензивных препаратов у больных эссенциальной гипертонией с сопутствующими факторами риска. Диссерт доктора мед наук. Москва 1997.Кобалава Ж.Д. Клиническое и фармакодинамическое обоснование выбора антигипертензивных препаратов у больных эссенциальной гипертонией с сопутствующими факторами риска. Диссерт доктора мед наук. Москва 1997.Дроздов В.Н. Обмен мочевой кислоты у больных гипертонической болезнью с метаболическим синдромом. Автореф диссерт канд мед наук. Москва 1999.Дроздов В.Н. Обмен мочевой кислоты у больных гипертонической болезнью с метаболическим синдромом. Автореф диссерт канд мед наук. Москва 1999.Караулова Ю.Л. Клинико-генетические детерминанты чувствительности/ устойчивости гипертрофии левого желудочка к антигипертензивной терапии. Автореф диссерт канд мед наук. Москва 2001.Караулова Ю.Л. Клинико-генетические детерминанты чувствительности/ устойчивости гипертрофии левого желудочка к антигипертензивной терапии. Автореф диссерт канд мед наук. Москва 2001.Iwashima Y, Horio T, Kamide K et al. Uric Acid, Left Ventricular Mass Index, and Risk of Cardiovascular Disease in Essential Hypertension. Hypertension 2006; 47; 195–202.Iwashima Y, Horio T, Kamide K et al. Uric Acid, Left Ventricular Mass Index, and Risk of Cardiovascular Disease in Essential Hypertension. Hypertension 2006; 47; 195–202.
The authors declare that there are no conflicts of interest present.